F. Mayer

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)

Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags

A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer

Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group

Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies

The role of liposomes in clinical nanomedicine development. What now? Now what?

Ovarian cancer

The development of platinum compounds and their possible combination

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials

A review of stimuli-responsive nanocarriers for drug and gene delivery

Stimuli-responsive nanocarriers for drug delivery

Nanocarriers as an emerging platform for cancer therapy

Current Management Strategies for Ovarian Cancer

Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results

Salvage Chemotherapy in Recurrent Platinum-Resistant or Refractory Epithelial Ovarian Cancer with Carboplatin and Distearoylphosphatidylcholine Pegylated Liposomal Doxorubicin (Lipo-Dox^®)

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

Nanotechnology: Intelligent Design to Treat Complex Disease

Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?

Doxil® — The first FDA-approved nano-drug: Lessons learned

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

Liposomes as nanomedical devices

Liposomal drug delivery systems: From concept to clinical applications

Surgical results of pelvic exenteration in the treatment of gynecologic cancer

Cervical cancer

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study

Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

Current Management Strategies for Ovarian Cancer

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens

Dissemination and publication of research findings: an updated review of related biases

Polymer-Caged Nanobins for Synergistic Cisplatin−Doxorubicin Combination Chemotherapy

Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?

Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer

Metal–Organic Frameworks in Biomedicine

Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications

First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up

Cellular uptake of nanoparticles: journey inside the cell

Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy

SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction

Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial

Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer

High-Dose Platinum versus Standard Dose in Advanced Ovarian Carcinoma: A Randomized Trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)

Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TOP) in first-line treatment of advanced ovarian cancer. Mature results of a Gynecologic Cancer Intergroup phase III trial of the AGO OVAR and GINECO

Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR): Survival results of a GINECO phase II trial

Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.

High dose chemotherapy in ovarian carcinoma